Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: No glucose infusion Clear all
Terminated Phase 1 Interventional Results available

Direct Peritoneal Resuscitation in Gastroschisis

NCT03205553
View directory record Official record
Conditions
Gastroschisis
Interventions
SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%
Procedure · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
0 Hours to 12 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 21, 2026, 9:06 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2015 · Synced Sep 21, 2026, 9:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolomic Analysis of Lung Cancer

NCT00263731
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Interventions
13-C-glucose
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids

NCT03912363
View directory record Official record
Conditions
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Interventions
Rotating fluids protocol, Insulin infusion protocol
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sympathetic Nerve Activity During Hypoglycemia and Exercise

NCT00608348
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Hyperinsulinemic glucose clamp procedures, moderate exercise
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 21, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AECOPD and Nutritional Supplementation in COPD

NCT06801964
View directory record Official record
Conditions
Obstructive Pulmonary Disease, Exacerbation Copd
Interventions
Stable isotope infusion, Protein and Fish Oil, Protein and Olive Oil, Carbohydrate and Olive Oil
Other · Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

DUR-928 in Patients With Alcoholic Hepatitis

NCT03917407
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 (Moderate AH), DUR-928 (Severe AH)
Drug
Lead sponsor
Craig James McClain
Other
Eligibility
21 Years to 67 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

NCT04617795
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Omnipod 5 Automated Insulin Delivery System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 21, 2026, 9:06 AM EDT
Not listed Phase 4 Interventional

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

NCT04414579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Faster Insulin Aspart (Fiasp®)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 21, 2026, 9:06 AM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery

NCT02204813
View directory record Official record
Conditions
Bypass, Gastric, Roux-en-Y Gastric Bypass, Vertical Sleeve Gastrectomy, Gastric Banding, Bariatric Surgery
Interventions
Placebo, Lo-Xenin, Hi-Xenin, Extra Hi-Xenin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 21, 2026, 9:06 AM EDT
Terminated Not applicable Interventional Results available

The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women

NCT04146909
View directory record Official record
Conditions
GDM, Lactation
Interventions
Hyperinsulinemic-euglycemic clamp
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Comparative Trial Between 3 Types of Insulin Infusion Protocols

NCT00582309
View directory record Official record
Conditions
Hyperglycemia
Interventions
Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chicago Heights, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

NCT01951729
View directory record Official record
Conditions
Pre-diabetes
Interventions
Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

NCT01660451
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

NCT03180307
View directory record Official record
Conditions
Ovarian Cancer
Interventions
OTL38, near infrared camera imaging system, laparotomy
Drug · Device · Procedure
Lead sponsor
On Target Laboratories, LLC
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial

NCT00941655
View directory record Official record
Conditions
Gastric Cancer
Interventions
Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Gastrectomy and/or metastasectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Results available

Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness

NCT00530023
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Loma Linda, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents

NCT01890954
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs)
Device
Lead sponsor
University of Virginia
Other
Eligibility
13 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

EASI Access II --- Follow-up Study to the EASI Access Trial

NCT00740727
View directory record Official record
Conditions
Disaster Medicine, Difficult Intravenous Access, Dehydration
Interventions
Human recombinant hyaluronidase (HRH), Enzymatically Augmented Subcutaneous Infusion (EASI) line placement
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2009 · Synced Sep 21, 2026, 9:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 21, 2026, 9:06 AM EDT